Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2097478 | 0.90 | ALDH1A1 (0.66) | KMT2AALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL17817424 | 0.84 | GAA (0.76) | POLBKMT2ANPSR1LMNAGAA | |
| SCHEMBL8368156 | 0.84 | GAA (0.76) | POLBKMT2ANPSR1LMNAGAA | |
| SCHEMBL8918895 | 0.84 | KMT2A (0.71) | POLBKMT2ANPSR1LMNAGAA | |
| SCHEMBL9316115 | 0.83 | POLB (0.69) | POLBKMT2ANPSR1LMNAGAA | |
| SCHEMBL6594370 | 0.81 | KMT2A (0.75) | POLBKMT2ANPSR1LMNAGAA | |
| SCHEMBL6593284 | 0.80 | KMT2A (0.69) | POLBKMT2ANPSR1LMNAGAA | |
| SCHEMBL3757797 | 0.79 | KMT2A (0.73) | POLBKMT2ANPSR1LMNAGAA | |
| SCHEMBL2098191 | 0.79 | NPC1 (0.63) | NPSR1LMNAALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL5807392 | 0.78 | KMT2A (0.75) | POLBKMT2ANPSR1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221206-A1 | Compounds Derived From Lidocaine, Pharmaceutical Compositions, Use And Method Of Treatment, Prevention Or Inhibition Of Disease | FUNDÇÃO OSWALDO CRUZ-FIOCRUZ (BR) | 2008-09-11 | — | — | US | claimed |
| EP-1831153-A2 | COMPOUNDS DERIVED FROM LIDOCAINE, PHARMACEUTICAL COMPOSITIONS, USE AND METHOD OF TREATMENT, PREVENTION OR INHIBITION OF DISEASES | FUNDA AO OSWALDO CRUZ-FIOCRUZ (BR) | 2007-09-12 | — | — | EP | claimed |
| WO-2005120148-A2 | COMPOUNDS DERIVED FROM LIDOCAINE, PHARMACEUTICAL COMPOSITIONS, USE AND METHOD OF TREATMENT, PREVENTION OR INHIBITION OF DISEASES | FUNDAÇÃO OSWALDO CRUZ-FIOCRUZ (BR) | 2005-12-22 | — | — | WO | claimed |
| US-8163803-B2 | less anesthetic activity, but with more anti-inflammatory and spasmolytic activity; asthma, rhinitis, allergic urticaria, chronic lung inflammation associated with eosinophilia, following the example of atopic asthma and chronic intestinal inflammation, as colitis for instance | Fundação Oswaldo Cruz—FIOCRUZ (BR) | 2012-04-24 | — | — | US | disclosed |
| US-20080221206-A1 | Compounds Derived From Lidocaine, Pharmaceutical Compositions, Use And Method Of Treatment, Prevention Or Inhibition Of Disease | FUNDÇÃO OSWALDO CRUZ-FIOCRUZ (BR) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221206-A1 | Compounds Derived From Lidocaine, Pharmaceutical Compositions, Use And Method Of Treatment, Prevention Or Inhibition Of Disease | LTA, LCT, LTC4S | POLB 2684/4885KMT2A 3557/4885NPSR1 2702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.